HIV entry inhibitors in clinical development - PubMed (original) (raw)

Review

HIV entry inhibitors in clinical development

Bryan M O'Hara et al. Curr Opin Pharmacol. 2002 Oct.

Abstract

Despite recent advances, present therapies for human immunodeficiency virus type 1 (HIV-1) infection are limited by their failure to eradicate HIV-1, by the emergence of multidrug-resistant variants and by significant toxicities. Current therapies collectively target two viral enzymes involved in intracellular viral replication processes, and there is an urgent need for new treatment modalities. HIV-1 entry is a multistep process that comprises viral attachment, co-receptor interactions and fusion. This cascade of events offers opportunities for therapeutic intervention, and clinical proof-of-principle has been obtained for inhibitors of each step. These agents are referred to broadly as entry inhibitors.

PubMed Disclaimer

Similar articles

• Opportunities and challenges in targeting HIV entry.
  Biscone MJ, Pierson TC, Doms RW. Biscone MJ, et al. Curr Opin Pharmacol. 2002 Oct;2(5):529-33. doi: 10.1016/s1471-4892(02)00200-x. Curr Opin Pharmacol. 2002. PMID: 12324254 Review.
• Inhibitors of viral entry.
  Melby T, Westby M. Melby T, et al. Handb Exp Pharmacol. 2009;(189):177-202. doi: 10.1007/978-3-540-79086-0_7. Handb Exp Pharmacol. 2009. PMID: 19048201 Review.
• The current status and challenges in the development of fusion inhibitors as therapeutics for HIV-1 infection.
  Tan JJ, Ma XT, Liu C, Zhang XY, Wang CX. Tan JJ, et al. Curr Pharm Des. 2013;19(10):1810-7. doi: 10.2174/1381612811319100005. Curr Pharm Des. 2013. PMID: 23092283 Review.
• Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
  Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Nagashima KA, et al. J Infect Dis. 2001 Apr 1;183(7):1121-5. doi: 10.1086/319284. Epub 2001 Mar 8. J Infect Dis. 2001. PMID: 11237840
• Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
  Müller JA, Glöckle A, Gawanbacht A, Geyer M, Münch J, Kirchhoff F. Müller JA, et al. J Virol. 2018 Aug 16;92(17):e00733-18. doi: 10.1128/JVI.00733-18. Print 2018 Sep 1. J Virol. 2018. PMID: 29925662 Free PMC article.

Cited by

• Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
  Ketas TJ, Frank I, Klasse PJ, Sullivan BM, Gardner JP, Spenlehauer C, Nesin M, Olson WC, Moore JP, Pope M. Ketas TJ, et al. J Virol. 2003 Feb;77(4):2762-7. doi: 10.1128/jvi.77.4.2762-2767.2003. J Virol. 2003. PMID: 12552019 Free PMC article.
• Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
  Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP. Kuhmann SE, et al. J Virol. 2004 Mar;78(6):2790-807. doi: 10.1128/jvi.78.6.2790-2807.2004. J Virol. 2004. PMID: 14990699 Free PMC article.
• Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
  Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, Pommier Y, Burke TR Jr, Pathak VK. Svarovskaia ES, et al. J Virol. 2004 Apr;78(7):3210-22. doi: 10.1128/jvi.78.7.3210-3222.2004. J Virol. 2004. PMID: 15016842 Free PMC article.
• Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.
  Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC. Jacobson JM, et al. Antimicrob Agents Chemother. 2004 Feb;48(2):423-9. doi: 10.1128/AAC.48.2.423-429.2004. Antimicrob Agents Chemother. 2004. PMID: 14742190 Free PMC article. Clinical Trial.
• Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.
  Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW. Reeves JD, et al. J Virol. 2004 May;78(10):5476-85. doi: 10.1128/jvi.78.10.5476-5485.2004. J Virol. 2004. PMID: 15113926 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information